Zimcík P, Miletín M
Katedra farmaceutické chemie a kontroly léciv Farmaceutické fakulty Univerzity Karlovy, Hradec Králové.
Ceska Slov Farm. 2004 Nov;53(6):271-9.
Since the time when hematoporphyrine derivative (trade name Photofrin) has been introduced into clinical practice in Canada in 1993, a lot of new photosensitizers (PS) have been studied. Some of them successfully passed the clinical trials and are in use in the treatment of cancerous (ALA, temoporfin) and non-cancerous (verteporfin) diseases. The others (motexafin lutecium, talaporfin, phthalocyanines and SnET2) are entering or passing the clinical trials now. The newer PS are also called the second generation PS, when the first generation is composed of Photofrin only. The second generation PS usually possesses better properties, especially concerning absorption at longer wavelengths, shorter skin photosensitivity, better accumulation ratio between tumorous and healthy tissue and pharmacokinetics.
自1993年血卟啉衍生物（商品名：光卟啉）在加拿大被引入临床实践以来，许多新型光敏剂（PS）已得到研究。其中一些已成功通过临床试验，并用于治疗癌症（如5-氨基酮戊酸、替莫泊芬）和非癌症（维替泊芬）疾病。其他的（莫特沙芬镥、他拉泊芬、酞菁类和二氢卟吩锡）目前正在进入或通过临床试验。当第一代仅由光卟啉组成时，更新的光敏剂也被称为第二代光敏剂。第二代光敏剂通常具有更好的性能，特别是在较长波长处的吸收、较短的皮肤光敏性、肿瘤组织与健康组织之间更好的蓄积率以及药代动力学方面。
